In their effort to answer a decades-old biological question about how the hepatitis B virus (HBV) is able to establish ...

Dynavax reports record HEPLISAV-B revenue, 26% growth in 2024, and strong 2025 guidance. Insights on shingles vaccine progress & market expansion.

Hong Kong health authorities have apologised for mistakenly giving pneumococcal vaccines to two children at a health centre ...

The hepatitis B vaccine is one of the very first vaccines your baby will get before she leaves the hospital. This vaccine protects her from a dangerous (but preventable!) liver infection and is given ...

Hepatitis A is a very contagious liver infection that is common in many parts of the world. Here's more about the vaccine for babies and kids.

The Department of Health is investigating and following up on an incident in which the pneumococcal vaccine was mistakenly ...

The Department of Health has apologised for mistakenly giving pneumococcal vaccines to two children who were supposed to get hepatitis B ...

HEPLISAV-B® 2024 net product revenue grew 26% year-over-year to $268 million; net product revenue expected to be $305 to $325 million in 2025 Top-line results in ...

Life sciences investment firm Deep Track Capital is launching a board fight at Dynavax Technologies, pressing for new ...

"We were delighted to discover not only important details about the mechanisms of HBV gene regulation, but also a promising ...